Live viral vector vaccine manufacturing is a complex, multistage process. Without expert process development and manufacturing support, there is a high risk of unforeseen challenges and issues leading to costly delays.


Therapeutic and prophylactic vaccine manufacturing

Pathogens such as viruses, bacteria, protozoans and worms, pose constant health concern. Renewed focus on infectious disease R&D is driving advancement of next-generation virus-like particles (VLPs) and traditional live-attenuated and inactivated viruses. Vibalogics can support comprehensive vaccine development and manufacturing whether for therapeutic or prophylactic use. We have vast experience using a wide range of viral platforms in development to deliver and express disease-related protein antigens to humans.

Virus and Vector Vaccine Experience

  • Dengue (DENV)
  • Influenza (Flu)
  • Infectious Bursal Disease (IBDV)
  • Infectious bronchitis virus (IBV)
  • Measles (Rubeola)
  • Newcastle Disease (NDV)
  • Respiratory-Syncitial Virus (RSV)
  • Poxviruses (MVA, Fowlpox)


We’re the ideal CDMO for your Viral Vector
Vaccine project

Get in touch


Looking for something different?

Vibalogics can assist you through a comprehensive service portfolio – ensuring the success of your virotherapy, beginning with process development and technical transfer feasibility, through cGMP production and validation.


Tackling Challenges to Successful Vaccine Development

Despite the impressive work done to find effective vaccines for a wide range of infectious diseases, there remain a number of illnesses that are difficult to prevent or treat. Examples include AIDS, malaria, tuberculosis, as well as norovirus and Zika virus infections, to name but a few.